Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
DVAX's Cash to Debt is ranked higher than
83% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. DVAX: No Debt )
DVAX' s 10-Year Cash to Debt Range
Min: 2.97   Max: No Debt
Current: No Debt

Equity to Asset 0.91
DVAX's Equity to Asset is ranked higher than
92% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. DVAX: 0.91 )
DVAX' s 10-Year Equity to Asset Range
Min: -2.28   Max: 0.93
Current: 0.91

-2.28
0.93
Interest Coverage No Debt
DVAX's Interest Coverage is ranked higher than
86% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. DVAX: No Debt )
DVAX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 10.00
M-Score: -2.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -590.95
DVAX's Operating margin (%) is ranked higher than
56% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. DVAX: -590.95 )
DVAX' s 10-Year Operating margin (%) Range
Min: -2150.61   Max: -37.49
Current: -590.95

-2150.61
-37.49
Net-margin (%) -593.01
DVAX's Net-margin (%) is ranked higher than
56% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. DVAX: -593.01 )
DVAX' s 10-Year Net-margin (%) Range
Min: -2100.73   Max: -56.15
Current: -593.01

-2100.73
-56.15
ROE (%) -35.81
DVAX's ROE (%) is ranked higher than
66% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. DVAX: -35.81 )
DVAX' s 10-Year ROE (%) Range
Min: -479.38   Max: -26.67
Current: -35.81

-479.38
-26.67
ROA (%) -32.61
DVAX's ROA (%) is ranked higher than
66% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. DVAX: -32.61 )
DVAX' s 10-Year ROA (%) Range
Min: -121.8   Max: -21.69
Current: -32.61

-121.8
-21.69
ROC (Joel Greenblatt) (%) -763.70
DVAX's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. DVAX: -763.70 )
DVAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2145.41   Max: -189.01
Current: -763.7

-2145.41
-189.01
Revenue Growth (%) -40.90
DVAX's Revenue Growth (%) is ranked higher than
59% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. DVAX: -40.90 )
DVAX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 88.2
Current: -40.9

0
88.2
EBITDA Growth (%) -20.20
DVAX's EBITDA Growth (%) is ranked higher than
65% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. DVAX: -20.20 )
DVAX' s 10-Year EBITDA Growth (%) Range
Min: -63.4   Max: 39.3
Current: -20.2

-63.4
39.3
EPS Growth (%) -18.00
DVAX's EPS Growth (%) is ranked higher than
70% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. DVAX: -18.00 )
DVAX' s 10-Year EPS Growth (%) Range
Min: -60.6   Max: 26.3
Current: -18

-60.6
26.3
» DVAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

DVAX Guru Trades in Q1 2013

Steven Cohen 6,996,857 sh (-25.1%)
» More
Q2 2013

DVAX Guru Trades in Q2 2013

Steven Cohen 3,827,918 sh (-45.29%)
» More
Q3 2013

DVAX Guru Trades in Q3 2013

John Burbank 63,492 sh (New)
Jim Simons 355,361 sh (New)
Steven Cohen 2,000,000 sh (-47.75%)
» More
Q4 2013

DVAX Guru Trades in Q4 2013

Jim Simons 1,562,513 sh (+339.7%)
Steven Cohen 7,577,533 sh (+278.88%)
John Burbank Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DVAX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-12-31 Sold Out 0.05%$1.11 - $2 $ 1.53%0
John Burbank 2013-09-30 New Buy$1.06 - $1.43 $ 1.519%63492
George Soros 2012-06-30 Sold Out 0.03%$3.55 - $5.21 $ 1.5-65%0
George Soros 2012-03-31 Reduce -62.5%0.09%$3.28 - $4.94 $ 1.5-60%375000
George Soros 2011-12-31 New Buy0.14%$1.82 - $3.33 $ 1.5-46%1000000
George Soros 2011-09-30 Sold Out 0.0026%$1.84 - $3.16 $ 1.5-39%0
George Soros 2011-06-30 New Buy$2.46 - $2.81 $ 1.5-43%66100
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.10
DVAX's P/B is ranked higher than
84% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. DVAX: 2.10 )
DVAX' s 10-Year P/B Range
Min: 0.64   Max: 14.73
Current: 2.1

0.64
14.73
P/S 26.20
DVAX's P/S is ranked lower than
68% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. DVAX: 26.20 )
DVAX' s 10-Year P/S Range
Min: 0.19   Max: 76.8
Current: 26.2

0.19
76.8
EV-to-EBIT 1.70
DVAX's EV-to-EBIT is ranked higher than
91% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. DVAX: 1.70 )
DVAX' s 10-Year EV-to-EBIT Range
Min: 0.4   Max: 6.1
Current: 1.7

0.4
6.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.30
DVAX's Price/Net Cash is ranked higher than
92% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. DVAX: 2.30 )
DVAX' s 10-Year Price/Net Cash Range
Min: 1.81   Max: 9.14
Current: 2.3

1.81
9.14
Price/Net Current Asset Value 2.30
DVAX's Price/Net Current Asset Value is ranked higher than
92% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. DVAX: 2.30 )
DVAX' s 10-Year Price/Net Current Asset Value Range
Min: 1.79   Max: 51.1
Current: 2.3

1.79
51.1
Price/Tangible Book 2.10
DVAX's Price/Tangible Book is ranked higher than
86% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. DVAX: 2.10 )
DVAX' s 10-Year Price/Tangible Book Range
Min: 1.68   Max: 28.4
Current: 2.1

1.68
28.4
Price/Median PS Value 2.20
DVAX's Price/Median PS Value is ranked lower than
62% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. DVAX: 2.20 )
DVAX' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 5.85
Current: 2.2

0.08
5.85
Earnings Yield (Greenblatt) 57.20
DVAX's Earnings Yield (Greenblatt) is ranked higher than
87% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. DVAX: 57.20 )
DVAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 16.5   Max: 231.2
Current: 57.2

16.5
231.2
Forward Rate of Return (Yacktman) -28.31
DVAX's Forward Rate of Return (Yacktman) is ranked higher than
67% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. DVAX: -28.31 )
DVAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -198.7   Max: -132.5
Current: -28.31

-198.7
-132.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DYF.Germany
Dynavax Technologies Corporation was incorporated in California in August 1996 under the name Double Helix Corporation, and it changed its name to Dynavax Technologies Corporation in September 1996. The Company reincorporated in Delaware in 2000. The Company is a clinical-stage biopharmaceutical company. It discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's product candidate is HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine. Its pipeline of product candidates includes: HEPLISAV, its autoimmune program partnered with GlaxoSmithKline, and its therapy for asthma partnered with AstraZeneca AB. Its product candidates are based on the use of immunostimulatory and immunoregulatory sequences. HEPLISAV is an investigational adult hepatitis B vaccine. In Phase 3 trials, HEPLISAV demonstrated higher and earlier protection with fewer doses than currently licensed vaccines. The Company has worldwide commercial rights to HEPLISAV. HEPLISAV combines its first generation 1018 ISS with hepatitis B surface antigen manufactured in its facility in Düsseldorf, Germany. The Company competes with pharmaceutical companies, biotechnology companies, academic institutions and research organizations, in developing therapies to prevent or treat infectious diseases and inflammatory and autoimmune diseases. Any product candidate it develops is subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA and foreign regulatory agencies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide